Erasca Inc. (ERAS)
1.97
0.04 (2.34%)
At close: Jan 15, 2025, 2:44 PM
Company Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme.
The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca Inc.
| Country | United States |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 126 |
| CEO | Dr. Jonathan E. Lim M.D. |
Contact Details
Address: 10835 Road to the Cure San Diego, California United States | |
| Website | https://www.erasca.com |
Stock Details
| Ticker Symbol | ERAS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001761918 |
| CUSIP Number | 29479A108 |
| ISIN Number | US29479A1088 |
| Employer ID | 83-1217027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & Chief Executive Officer |
| Dr. David M. Chacko M.D. | Chief Financial Officer & Chief Business Officer |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research & Development, Scientific Advisory Board Member and Director |
| Dr. Robert Shoemaker Ph.D. | Senior Vice President of Research |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Ebun S. Garner Esq., J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |